ArticleFrontiers in medicine2025
Clinical characteristic, treatment, and mortality among cancer and non-cancer patients presented with incidental pulmonary embolism.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer patients are at an increased risk of developing venous thrombosis Advances in multidetector computed tomography (CT) scanners have facilitated the detection of pulmonary embolism (PE). However, the natural course of incidental PE (IPE), particularly in cancer patients, remains controversial. Methods: This retrospective cohort study was conducted at a tertiary medical center in Thailand. Patients aged 15 years or older who were diagnosed with PE between 2011 and 2020 were included. The study population was divided into two groups: the IPE group and the suspected PE (SPE) group. The primary outcome was 30-day mortality. Results: A total of 736 patients with acute PE were included in the analysis, with 281 classified as having IPE and 455 as having SPE. Active cancer was more prevalent in the IPE group compared to the SPE group (70.8% vs. 46.6%, Conclusion: IPE is common in cancer and is associated with delayed anticoagulation but similar adjusted short-term mortality to SPE. System-level pathways to expedite treatment for IPE may improve care, especially in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.